Replies to post #300394 on Avid Bioservices Inc (CDMO)

[keep_trying]

It looks like the Russell 3000 cutoff was at 143.6 million. Of course, pls was under a buck.

Best wishes and IMO.
KT

[biopharm]

MRI images critically important so Fujifilm, we welcome you aboard with any offers you may have for investments as well : )

... Fujifilm Diosynth Biotechnologies ...

Are we being tipped to whom one of our initial, future partners may be?

http://www.fujifilmdiosynth.com

...and I bet Roger Lias knows liposomes contain Phosphatidylserine
https://www.ncbi.nlm.nih.gov/pubmed/20176740

____________________

September 11, 2017
Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices
...
...
Throughout his career, Dr. Lias has held senior management positions at several leading CDMOs including Cytovance Biologics, KBI BioPharma, Diosynth RTP (formerly Covance Biotechnology Services) and Lonza Biologics. At each of these companies, he was primarily charged with overseeing commercial operations, including growing and diversifying their respective client bases. During this time, Dr. Lias' achievements ranged from building start-up Cytovance's contract process development and biopharmaceutical cGMP production business, to increasing revenues at Diosynth from $16 million to $120 million over a four-year period. Additionally, he has built a reputation as a highly regarded CDMO industry advocate who has contributed to the acceptance and growth of the biologics contract manufacturing market. Dr. Lias earned his Ph.D. from Clare College at the University of Cambridge in the United Kingdom.
..
..
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1039872

-------

Cristina Brinkmann ex-Xencor and I am trying to see more clearly like those new MRI flipped PS Targeting may be doing....but since new Roger Lias President has Diosynth

https://www.linkedin.com/in/beth-jones-a1540a14

...as usual, lots of puzzle pieces to place and analyze and it is more difficult a bit with research gate locked down to see who those new followers are to key researchers of PS Targeting but it only means PS Targeting may be just as important as ever before

[biopharm]

Have current BODs at Peregrine Pharmaceuticals been reading up all information possible at their legal access, in order to fulfill Fiduciary Duties when the time comes to value all company IP such as PS Targeting and it's broad use ?

Current BODs must get up to speed quickly in order to legally recommend, approve, vote....etc on any company business negotiations in order to maximize shareholder value.

_____

Targeting Phosphatidylserine with a 64Cu-Labeled Peptide for Molecular Imaging of Apoptosis

Amanda Perreault, Susan Richter, Cody Bergman, Melinda Wuest and Frank Wuest*
*E-mail: [e-mail].

Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, Alberta T6G 2X4, Canada
Molecular Pharmaceutics

Vol. 13: , Issue. 10, : Pages. 3564-3577
Publication Date (Web): September 8, 2016

DOI: 10.1021/acs.molpharmaceut.6b00666

Molecular imaging of programmed cell death (apoptosis) in vivo is an innovative strategy for early assessment of treatment response and treatment efficacy in cancer patients. Externalization of phosphatidylserine (PS) to the cell membrane surface of dying cells makes this phospholipid an attractive molecular target for the development of apoptosis imaging probes. In this study, we have radiolabeled PS-binding 14-mer peptide FNFRLKAGAKIRFG (PSBP-6) with positron-emitter copper-64 (64Cu) for PET imaging of apoptosis. Peptide PSBP-6 was conjugated with radiometal chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) through an aminovaleric acid (Ava) linker for subsequent radiolabeling with 64Cu to prepare radiotracer 64Cu-NOTA-Ava-PSBP-6. PS-binding potencies of PSBP-6, NOTA-Ava-PSBP-6, and natCu-NOTA-Ava-PSBP-6 were determined in a competitive radiometric PS-binding assay. Radiotracer 64Cu-NOTA-Ava-PSBP-6 was studied in camptothecin-induced apoptotic EL4 mouse lymphoma cells and in a murine EL4 tumor model of apoptosis using dynamic PET imaging. Peptide PSBP-6 was also conjugated via an Ava linker with fluorescein isothiocyanate (FITC). FITC-Ava-PSBP-6 was evaluated in flow cytometry and fluorescence confocal microscopy experiments. Radiopeptide 64Cu-NOTA-Ava-PSBP-6 was synthesized in high radiochemical yields of >95%. The IC50 values for PS-binding potency of PSBP-6, NOTA-Ava-PSBP-6, and natCu-NOTA–PSBP-6 were 600 µM, 30 µM, and 23 µM, respectively. A competitive radiometric cell binding assay confirmed binding of 64Cu-NOTA-Ava-PSBP-6 to camptothecin-induced apoptotic EL4 cells in a Ca2+-independent manner. PET imaging studies demonstrated significantly higher uptake of 64Cu-NOTA-Ava-PSBP-6 in apoptotic EL4 tumors (SUV5min 0.95 ± 0.04) compared to control tumors (SUV5min 0.74 ± 0.03). Flow cytometry studies showed significantly higher binding of FITC-Ava-PSBP-6 to EL4 cells treated with camptothecin compared to untreated cells. Fluorescence microscopy studies revealed that FITC-Ava-PSBP-6 was binding to cell membranes of early apoptotic cells, but was internalized in late apoptotic and necrotic cells. The present study showed that radiotracer 64Cu-NOTA-Ava-PSBP-6 holds promise as a first peptide-based PET imaging agent for molecular imaging of apoptosis. However, additional “fine-tuning” of 64Cu-NOTA-Ava-PSBP-6 is required to enhance PS-binding potency and in vivo stability to improve tumor uptake and retention.

http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.6b00666?src=recsys&journalCode=mpohbp